Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George M Solomon

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
American Journal of Physiology. Lung Cellular and Molecular Physiology|June 11, 2024
Metachrony drives effective mucociliary transport via a calcium-dependent mechanismJacelyn E Peabody Lever, K Brett Turner, Courtney M Fernandez, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|January 9, 2026
Development of a Novel Potential Difference Probe with Bedside Validation Simulator for Potential Difference TestingDavid O Otuya, Kadambari Vijaykumar, Justin Anderson, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 7, 2025
Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise studyJennifer T Duong, Hillary S Hayden, Adrian J Verster, et al.
Chest|May 18, 2010
An international randomized multicenter comparison of nasal potential difference techniquesGeorge M Solomon, Michael W Konstan, Michael Wilschanski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 3, 2017
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbationsDon B Sanders, George M Solomon, Valeria V Beckett, et al.
Annals of the American Thoracic Society|September 17, 2025
Long-term Reductions in Inflammation in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/IvacaftorScott D Sagel, T Spencer Poore, Brandie D Wagner, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 24, 2018
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P Clancy, David P Nichols, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 13, 2016
Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomySusan E Birket, Kengyeh K Chu, Grace H Houser, et al.
American Journal of Human Genetics|May 6, 2017
Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice SitesMelissa Lee, Patrick Roos, Neeraj Sharma, et al.
Annals of the American Thoracic Society|June 11, 2026
Elexacaftor-Tezacaftor-Ivacaftor for Individuals with Residual CFTR Activity: An Open-Label, Nonrandomized Clinical TrialRachel W Linnemann, George M Solomon, Adrianna L Westbrook, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
American Journal of Physiology. Lung Cellular and Molecular Physiology|June 11, 2024
Metachrony drives effective mucociliary transport via a calcium-dependent mechanismJacelyn E Peabody Lever, K Brett Turner, Courtney M Fernandez, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|January 9, 2026
Development of a Novel Potential Difference Probe with Bedside Validation Simulator for Potential Difference TestingDavid O Otuya, Kadambari Vijaykumar, Justin Anderson, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 7, 2025
Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise studyJennifer T Duong, Hillary S Hayden, Adrian J Verster, et al.
Chest|May 18, 2010
An international randomized multicenter comparison of nasal potential difference techniquesGeorge M Solomon, Michael W Konstan, Michael Wilschanski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 3, 2017
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbationsDon B Sanders, George M Solomon, Valeria V Beckett, et al.
Annals of the American Thoracic Society|September 17, 2025
Long-term Reductions in Inflammation in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/IvacaftorScott D Sagel, T Spencer Poore, Brandie D Wagner, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 24, 2018
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P Clancy, David P Nichols, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 13, 2016
Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomySusan E Birket, Kengyeh K Chu, Grace H Houser, et al.
American Journal of Human Genetics|May 6, 2017
Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice SitesMelissa Lee, Patrick Roos, Neeraj Sharma, et al.
Annals of the American Thoracic Society|June 11, 2026
Elexacaftor-Tezacaftor-Ivacaftor for Individuals with Residual CFTR Activity: An Open-Label, Nonrandomized Clinical TrialRachel W Linnemann, George M Solomon, Adrianna L Westbrook, et al.
Pageof 9